MV

Maithili Vijay Indargi

Active Director Additional Director DIN 11458734
DIN 11458734 First appointment Jan 2026 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Maithili Vijay Indargi

Data last updated:

Maithili Vijay Indargi is an Additional Director at Akrivis Lifescience Private Limited (since 2026). The company operates in Pharma.

DIN 11458734
Primary Designation Additional Director
Industry Pharma
First Appointment 01 Jan 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Akrivis Lifescience Private Limited U47721MH2023PTC414466
Additional Director01 Jan 2026Active

Board colleagues of Maithili Vijay Indargi

NameDINCompanyDesignation
Kamani Satish Somavanshi10406319Akrivis Lifescience Private LimitedDirector

Directorship timeline

Open interactive timeline →
Akrivis Lifescience Private Limited
Premium access

Shareholding and investment profile for Maithili Vijay Indargi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Maithili Vijay Indargi

Maithili Vijay Indargi currently holds 1 directorship: Akrivis Lifescience Private Limited (Additional Director, since 01 Jan 2026).

Maithili Vijay Indargi was first appointed on 01 Jan 2026 as Additional Director at Akrivis Lifescience Private Limited.

The current boards of Maithili Vijay Indargi's companies include Kamani Satish Somavanshi (Akrivis Lifescience Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available